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A genome-wide association study 
of anorexia nervosa suggests a risk 
locus implicated in dysregulated 
leptin signaling
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Fengxiang Wang1, James Snyder1, Maria Lemma1, Cuiping Hou1, Zhi Wei1, Yiran Guo  1, 
Haijun Qiu1, Frank D. Mentch1, Kelly A. Thomas1, Rosetta M. Chiavacci1, Roger Cone2,5, 
Bingshan Li2, Patrick A. Sleiman1, Eating Disorders Working Group of the Psychiatric 
Genomics Consortium*, Price Foundation Collaborative Group* & Hakon Hakonarson1,3,4
We conducted a genome-wide association study (GWAS) of anorexia nervosa (AN) using a stringently 
defined phenotype. Analysis of phenotypic variability led to the identification of a specific genetic 
risk factor that approached genome-wide significance (rs929626 in EBF1 (Early B-Cell Factor 1); 
P = 2.04 × 10−7; OR = 0.7; 95% confidence interval (CI) = 0.61–0.8) with independent replication 
(P = 0.04), suggesting a variant-mediated dysregulation of leptin signaling may play a role in AN. 
Multiple SNPs in LD with the variant support the nominal association. This demonstrates that although 
the clinical and etiologic heterogeneity of AN is universally recognized, further careful sub-typing of 
cases may provide more precise genomic signals. In this study, through a refinement of the phenotype 
spectrum of AN, we present a replicable GWAS signal that is nominally associated with AN, highlighting 
a potentially important candidate locus for further investigation.
Anorexia nervosa (AN) is a complex and often chronic eating disorder characterized by inability to maintain a 
normal healthy body weight and a persistent fear of weight gain, resulting in extreme emaciation and even death 
in some cases1. Previous genetic and epidemiological studies have indicated a multifactorial etiology, where both 
genetic and environmental factors contribute to disease risk2–7.
As sample sizes have increased, genome-wide association studies (GWASs) of AN have begun to identify 
risk variants8–10. To further elucidate the genetic architecture of AN, we performed a GWAS using data from our 
previously published study8 consisting of 1,033 AN cases by excluding 212 patients with AN who experienced 
diagnostic crossover during the course of their illness. Specifically, we excluded patients who migrated from or 
to binge-eating disorder (BED) or bulimia nervosa (BN) as assessed with the Structured Interview for Anorexic 
and Bulimic Disorders11). Although a previous study indicated women with BN were rarely to cross over to AN12, 
we observed ~43% of AN/BN crossover cases falls into this category in our cohort, suggestive of a confounding 
factor. We hypothesized that this reduction in phenotypic heterogeneity, despite the fact that AN and BN may 
share some genetic risk factors13, would enhance gene discovery.
Results
Our discovery cohort included a total of 692 female AN cases of non-Hispanic European (NHE) descent. Cases 
were included if they were diagnosed with restricting type and binge eating/purging type of AN as defined by 
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DSM-IV. Both types are characterized by below-normal weight and restricted food intake. Individuals diagnosed 
as restricting type do not experience binge-eating episodes and do not engage in purging, such as vomiting or use 
of laxatives. Standard quality controls measures were applied, specifically, excluding potential cryptic relatedness 
and checking for population stratification (details described elsewhere8). The average age of onset of the case sub-
jects was 16.3 years with a standard deviation (SD) of 3 years (Interquartile Range; IQR = 16(14–18)). The control 
group included 3,570 female matched healthy adolescents of NHE ancestry that had an average age of 18.3 years 
at the time of data analysis (SD = 5.7; IQR = 19(13–23)) (Supplementary Table 1). Associations were assessed 
with 507,999 SNPs genotyped on either Illumina HumanHap550 or Human610-Quad BeadChips in an additive 
model using logistic regression analyses with principal components adjustment, based on the principal compo-
nent analysis of cases and controls (Supplementary Figure 1), resulting in significantly low level of genomic con-
trol inflation factor of 1.03 (Supplementary Figure 2). The analysis yielded one SNP (rs929626) with a P value of 
2.04 × 10−7 and 4 other SNPs with marginally larger P values that are in strong linkage disequilibrium (r2 > 0.8); 
these SNPs were selected for further analysis (Supplementary Figure 3; Supplementary Table 2).
Using imputation analysis based on data from the 1000 Genomes Project (Phase I integrated variant set, 
v2, March 2012), we subsequently tested associations with SNPs (imputed info > 0.5, minor allele frequency 
(MAF) > 0.05) located in a 200-kb window centered on the SNP rs929626. We observed association with a series 
of markers around this region, of which 34 SNPs supported suggestive associations (P < 1.0 × 10−6) with both 
imputed and genotyped SNPs, which were in high LD with AN (Fig. 1; Supplementary Table 3). This suggests that 
the single markers demonstrating nominal association in the GWAS are likely to be true positives.
We further explored this finding using the meta-analysis results from 15 previously reported AN cohorts10. 
Interestingly, two SNPs were also nominally significant (rs929626 with P = 0.037 and rs17543752 with P = 0.05) 
in the same direction as in the GWAS (Table 1). Meta-analysis results in a P value of 1.52 × 10−7.
We next used the ENCODE project14 data to predict possible functional effect of the SNPs identified in this 
study. The top SNP, rs929626, and other significant markers located in the 6th intron of the EBF1 gene (Early 
B-Cell Factor 1), as well as two SNPs (rs113252656 and rs1081071) flanking the top SNP rs929626 at r2 > 0.5 
function as binding sites for EBF1 itself (HaploReg v4.1; ref. 15). This suggests that these genetic variants may 
modulate the expression of EBF1. Indeed, we observed a positive correlation with the rs929626 C allele car-
riers compared with TT homozygotes on the EBF1 expression level in nine independent subjects (the FPKM 
Figure 1. Region of genome-wide nominal association at 5q33.3. Regional plot of the EBF1-associated interval 
for the imputation analysis. Foreground shows scatter plot of the −log10 P values plotted against physical 
position of human reference hg19. Background shows estimated recombination rates plotted to reflect the local 
LD structure. The color of the dots represents the strength of LD between the top SNP (rs929626) and its proxies 
(red, r2 ≥ 0.8; orange, 0.8 > r2 ≥ 0.6; green, 0.6 > r2 ≥ 0.4; blue and navy, r2 < 0.4). Genes, position of exons, and 
direction of transcription from UCSC genome browser (http://genome.ucsc.edu) are noted.
SNP Study MA OR SE L95 U95 P
rs929626
CHOP C 0.7004 0.06855 0.6123 0.8011 2.04E-07
PGC-ED C 0.938252 0.027953 0.883465 0.996437 0.037887
Table 1. Association results for the lead genotyped SNP. Abbreviations: MA, minor allele; OR, odds ratio; SE, 
standard error; L95, lower 95% confidence interval; U95, upper 95% confidence interval; P, P-value.
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value for TT homozygotes (3 subjects) versus C allele carriers (6 individuals) is 5.0 versus 6.4) with both whole 
genome sequencing data of blood and corresponding RNA-Seq data of heart right ventricle selected from the 
Pediatric Cardiac Genomics Consortium cohort (dbGaP Study Accession: phs000571.v3.p2). By using the 
Genotype-Tissue Expression Portal database (http://www.gtexportal.org), we also observed nominally signifi-
cant expression quantitative trait loci (eQTLs) association (P = 0.0024, tested in 97 samples) in the putamen for 
rs929626 in the same direction. A few comorbid psychiatric disorders have been linked with the function of the 
putamen, such as anxiety, obsessive-compulsive disorder and attention deficit-hyperactivity disorder16–18. Taken 
together, these suggest the minor allele C carriers have relatively higher EBF1 expression.
Discussion
EBF1 encodes a transcription factor that originally thought to function as necessary for the development of the 
immune system19, but it has since been shown to regulate the development of both osteoblast and adipocyte 
lineages20–22. Two EBF1 variants, rs11953630-T and rs9313772-T, showed significant association at genome-wide 
level (P < 5 × 10−10) in a study testing blood pressure in European whites23, 24. In addition, rs17056278-C was 
also identified as a metabolic risk allele, interacting with psychosocial stress to contribute to increased hip cir-
cumference (P = 3 × 10−8)25. However none of these is in LD with any markers in our identified locus. In animal 
studies, Ebf1−/− mice showed increased adipose tissue within marrow, whereas peripheral white adipose tissue 
was severely reduced. Circulating levels of leptin, a hormone released by adipocytes and one of the major players 
in food intake regulation, were also decreased in Ebf1−/− mice compared with controls26. This concurs with 
the reported generalized loss of accumulation of subcutaneous and visceral adipose accompanied by significant 
increases in yellow marrow in AN patients27, 28. Also notable is the finding that circulating levels of leptin are very 
low in AN patients29, 30 and a decline in levels of circulating leptin can lead to changes in brain activity in areas 
involved in regulatory, emotional, and cognitive control of appetite5.
Understanding the genetics of AN is currently a major within-field initiative, in parallel to other neuropsy-
chiatric/neurodevelopmental disorders such as schizophrenia, bipolar disorder, and autism spectrum disorders. 
Although the clinical and etiologic heterogeneity is universally recognized, in practice, many studies still failed to 
account for sample heterogeneity. In this study, by focusing on individuals with AN who have not crossed over to 
BN or BED, we have identified a marginally replicating GWAS signal that approached genome-wide significance. 
One limitation of our study is that all participants may not yet have experienced the full course of their eating 
disorder (The average duration of follow-up was 8.6 years with a SD of 7.0 years in the discovery cohort, while 
the average crossover time was 2.8 years with a SD of 2.6 years for the excluded AN patients), and a portion of the 
sample may develop BN or BED at later stages of illness. This would represent a conservative bias and underscores 
the importance of further investigation of this locus in the future focusing on individuals with lifetime AN who 
have never crossed over to other eating disorder presentations.
Methods
Discovery data set and quality control. We conducted a GWAS using data from our previously pub-
lished study8 consisting of 1,033 AN cases by excluding 212 patients with AN who experienced diagnostic cross-
over during the course of their illness (i.e. migrated from or to binge-eating disorder (BED) or bulimia nervosa 
(BN) as assessed with the Structured Interview for Anorexic and Bulimic Disorders11) plus 100 patients without 
such information. A total of 692 female AN cases and 3,570 female matched controls that were carefully selected 
from Center for Applied Genomics (CAG) database were included in the analysis after Standard quality controls, 
namely, excluding potential cryptic relatedness and checking for population stratification by using the PLINK 
software31 version 1.90a. The Research Ethics Board of CHOP and other participating centers approved the study. 
Informed consent was obtained from all adult participants and from a parent or legal guardian in the case of chil-
dren and all work followed was in accordance with an IRB-approved protocol.
Association tests. For the genome-wide association analysis for SNPs, we utilized the PLINK software31 
version 1.90a, through Cochran–Armitage trend test.
Expression studies. The extended locus around associated SNP was then defined by identification of all 
SNPs showing r2 > 0.5. Linkage disequilibrium (LD) was defined with the HaploReg v4.1 (ref. 15) based on Phase 
I of the 1000 Genomes project. Variants showing evidence of LD with associated AN variants were explored for 
impact on gene function via regulatory function (including eQTLs) by HaploReg v4.1, which both collate data 
from the Encyclopedia of DNA Elements (ENCODE)14. We also referred to the Genotype-Tissue Expression 
Portal database (http://www.gtexportal.org) for eQTLs analysis.
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